Gilead (GILD) Rips Following GS-7977 Update
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Join SI Premium – FREE
Gilead Sciences (Nasdaq: GILD) is ripping pre-market Thursday following an update on its proposed treatment for genotype 1 chronic hepatitis C virus (HCV) infection, GS-7977.
According to the release, "the study found that 90 percent of patients (n=47/52, missing data equals failure analysis) achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load (HCV RNA <25 IU/mL) 12 weeks after the completion of therapy."
Shares are up over 14 percent early. For more color on the release, click here.
According to the release, "the study found that 90 percent of patients (n=47/52, missing data equals failure analysis) achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load (HCV RNA <25 IU/mL) 12 weeks after the completion of therapy."
Shares are up over 14 percent early. For more color on the release, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
